更新于：2024-06-23
Micafungin Sodium
米卡芬净钠
更新于：2024-06-23
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C56H71N9NaO23S |
InChIKeyPWAXVQURCGJSNE-WZPXRXMFSA-N |
CAS号208538-73-2 |
序列信息
Sequence Code 524728241
关联
78
项与 米卡芬净钠 相关的临床试验Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized Trial
一项在念珠菌血症和/或侵袭性念珠菌病患者中比较两项治疗方案（静脉注射棘白菌素后 口服Ibrexafungerp 和静脉注射棘白菌素后口服氟康唑）的III 期、多中心、前瞻性、随 机、双盲研究（MARIO）
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates: A Randomized Control Trial
100 项与 米卡芬净钠 相关的临床结果
登录后查看更多信息
100 项与 米卡芬净钠 相关的转化医学
登录后查看更多信息
100 项与 米卡芬净钠 相关的专利（医药）
登录后查看更多信息
1,808
项与 米卡芬净钠 相关的文献（医药）2024-06-01Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Invasive fungal infection caused by Blastobotrys mokoenaii in an immunocompromised patient with acute myeloid leukemia: A case report
作者: Noura, Ikue ; Shiomi, Ichiro ; Nakashima, Yasuhiro ; Kakeya, Hiroshi ; Kaimi, Yuto ; Kakuno, Shigeki ; Kohashi, Kenichi ; Ido, Kentaro ; Makuuchi, Yosuke ; Okamura, Hiroshi ; Niki, Makoto ; Takakuwa, Teruhito ; Nishimoto, Mitsutaka ; Nakamae, Hirohisa ; Nakamae, Mika ; Sakatoku, Kazuki ; Kuno, Masatomo ; Hino, Masayuki
Blastobotrys is a genus of rare yeast that is increasingly recognized as a cause of fungal infections in humans. However, there have been no reports of fungal infections in humans caused by Blastobotrys mokoenaii. We describe a case of invasive fungal infection (IFI) caused by B. mokoenaii in an immunocompromised patient with acute myeloid leukemia (AML). A 46-year-old man with relapsed/refractory AML underwent a second allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT) during remission. The patient had prolonged neutropenia and received systemic steroid therapy for graft-versus-host disease before the second allo-PBSCT. Uncommon yeast was isolated from the blood cultures obtained on day 4. We initially suspected that the uncommon yeast was Trichosporon spp. based on its morphology. However, unlike Trichosporon spp., in vitro antifungal susceptibility tests showed that this yeast isolate was resistant to micafungin, caspofungin, voriconazole, itraconazole, and fluconazole. We performed DNA sequencing and identified it as B. mokoenaii. B. mokoenaii was persistently isolated from blood cultures taken during combination therapy with liposomal amphotericin B and voriconazole. The patient died of multiorgan failure on day 24. B. mokoenaii can cause severe IFI in immunocompromised patients; however, it may not be correctly identified by routine clinical microbiology testing in a hospital laboratory and DNA sequencing is useful for diagnosis.
2024-03-06Antimicrobial agents and chemotherapy
Limitations of antifungal prophylaxis in preventing invasive
Candida
surgical site infections after liver transplant surgery
Article
作者: Arif, S ; Sudan, D L ; Alexander, B D ; Evans, K ; Miller, R A ; Harris, M ; Barbas, A S ; Perfect, J R ; Carugati, M ; Yarrington, M E ; King, L Y
ABSTRACT:
Invasive primary
Candida
surgical site infections (IP-SSIs) are a common complication of liver transplantation, and targeted antifungal prophylaxis is an efficient strategy to limit their occurrence. We performed a retrospective single-center cohort study among adult single liver transplant recipients at Duke University Hospital in the period between 1 January 2015 and 31 December 2020. The study aimed to determine the rate of
Candida
IP-SSI according to the peri-transplant antifungal prophylaxis received. Of 470 adult single liver transplant recipients, 53 (11.3%) received micafungin prophylaxis, 100 (21.3%) received fluconazole prophylaxis, and 317 (67.4%) did not receive systemic antifungal prophylaxis in the peri-transplant period. Ten
Candida
IP-SSIs occurred among 5 of 53 (9.4%) micafungin recipients, 1 of 100 (1.0%) fluconazole recipients, and 4 of 317 (1.3%) recipients who did not receive antifungal prophylaxis. Our study highlights the limitations of antifungal prophylaxis in preventing invasive
Candida
IP-SSI after liver transplant surgery. We hypothesize that pathogen, host, and pharmacokinetic-related factors contributed to the occurrence of
Candida
IP-SSI despite antifungal prophylaxis. Our study reinforces the need for a risk-based, multi-pronged approach to fungal prevention, including targeted antifungal administration in patients with risks for invasive candidiasis and close monitoring, especially among patients with surgically complex procedures, with timely control of surgical leaks.
2024-02-01International journal of antimicrobial agents
The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: A systematic review
Review
作者: Kohlhauer, Matthias ; De Roux, Quentin ; Pressiat, Claire ; Jendoubi, Ali ; Hulin, Anne ; Mongardon, Nicolas ; Ghaleh, Bijan ; Tissier, Renaud
BACKGROUND AND OBJECTIVE:
The use of extracorporeal membrane oxygenation (ECMO) as a cardiocirculatory or respiratory support has tremendously increased in critically ill patients. In the setting of ECMO support, invasive fungal infections are a severe cause of morbidity and mortality. This vulnerable population is at risk of suboptimal antifungal exposure due to an increased volume of distribution (Vd), drug sequestration and decreased clearance. Here, we aimed to summarize ex-vivo and clinical studies on the potential impact of ECMO on the pharmacokinetics (PK) of antifungal agents and dosing requirements.
METHODS:
A systematic search of the literature within electronic databases PubMed and EMBASE was conducted from database inception to 30 April 2023. Inclusion criteria were as follows: critically ill patients receiving ECMO regardless of age and reporting at least one PK parameter.
RESULTS:
Thirty-six studies met inclusion criteria, including seven ex-vivo experiments and 29 clinical studies evaluating three classes of antifungals: polyenes, triazoles and echinocandins. Based on the available ex-vivo PK data, we found a significant sequestration of highly lipophilic and protein-bound antifungals within the ECMO circuit such as voriconazole, posaconazole and micafungin but the PK of several antifungals remains to be addressed such as amphotericin B, isavuconazole and anidulafungin. Most clinical studies have shown increased Vd of some antifungals like fluconazole and micafungin, particularly in the pediatric population. Conflicting data exist about caspofungin exposure.
CONCLUSIONS:
The available literature on the antifungal PK changes in ECMO setting is scarce. Whenever possible, therapeutic drug monitoring is highly advised to personalize antifungal therapy.
100 项与 米卡芬净钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 系统性念珠菌病 | 美国 | 2021-06-16 | |
| 系统性念珠菌病 | 美国 | 2021-06-16 | |
| 系统性念珠菌病 | 美国 | 2021-06-16 | |
| 食管念珠菌病 | 欧盟 | 2008-04-25 | |
| 食管念珠菌病 | 冰岛 | 2008-04-25 | |
| 食管念珠菌病 | 列支敦士登 | 2008-04-25 | |
| 食管念珠菌病 | 挪威 | 2008-04-25 | |
| 侵袭性念珠菌病 | 欧盟 | 2008-04-25 | |
| 侵袭性念珠菌病 | 冰岛 | 2008-04-25 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2008-04-25 | |
| 侵袭性念珠菌病 | 挪威 | 2008-04-25 | |
| 脓肿 | 美国 | 2008-01-22 | |
| 念珠菌腹膜炎 | 美国 | 2008-01-22 | |
| 念珠菌血症 | 美国 | 2008-01-22 | |
| 曲霉菌病 | 日本 | 2002-10-08 | |
| 念珠菌病 | 日本 | 2002-10-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 口腔念珠菌病 | 临床3期 | 巴西 | 2003-08-01 | |
| 口腔念珠菌病 | 临床3期 | 秘鲁 | 2003-08-01 | |
| 口腔念珠菌病 | 临床3期 | 南非 | 2003-08-01 | |
| 侵袭性真菌感染 | 临床3期 | 美国 | 2003-01-01 | |
| 侵袭性真菌感染 | 临床3期 | 加拿大 | 2003-01-01 | |
| 侵袭性曲霉菌病 | 临床2期 | 奥地利 | 1999-01-29 | |
| 侵袭性曲霉菌病 | 临床2期 | 法国 | 1999-01-29 | |
| 侵袭性曲霉菌病 | 临床2期 | 德国 | 1999-01-29 | |
| 侵袭性曲霉菌病 | 临床2期 | 意大利 | 1999-01-29 | |
| 侵袭性曲霉菌病 | 临床2期 | 波兰 | 1999-01-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 35 | 選製製範糧範壓網獵繭(顧顧憲築鑰範鏇糧襯艱) = 鏇淵襯蓋築鬱選鬱蓋糧 範築網鑰鬱簾網繭壓簾 (範選鹽構窪鏇淵網壓範 ) | 积极 | 2021-03-18 | |||
临床4期 | 36 | (Subjects Recieving 100 mg of Micafungin) | 範願膚壓淵膚獵蓋繭窪(顧範憲鹹鹽繭淵夢窪艱) = 顧構觸鑰願糧鏇齋醖鹽 鏇衊鏇構獵鹽獵艱齋製 (遞鹽觸繭繭壓廠獵壓製, 願窪齋遞衊襯壓簾鏇衊 ~ 網鏇範窪餘選簾壓顧繭) 更多 | - | 2020-11-27 | ||
(Subjects Recieving 300 mg of Micafungin) | 範願膚壓淵膚獵蓋繭窪(顧範憲鹹鹽繭淵夢窪艱) = 顧築鹹網遞廠齋齋鹹網 鏇衊鏇構獵鹽獵艱齋製 (遞鹽觸繭繭壓廠獵壓製, 醖夢餘製鹽鏇蓋窪網選 ~ 築鑰糧餘壓鹹餘築淵範) 更多 | ||||||
临床3期 | - | 172 | 鹹構蓋齋醖膚簾膚醖網(窪範夢簾選願獵窪觸簾) = A total of 17 drug-related adverse events were observed in both groups; none of them was serious and all resolved. 範鏇顧廠憲壓積網顧選 (艱廠範蓋餘廠廠淵鑰願 ) | 积极 | 2020-04-01 | ||
临床4期 | 24 | (Normal-weight healthy subjects) | 簾淵選齋淵鬱網糧餘觸(齋觸襯醖壓夢襯顧簾糧) = 簾製觸簾選夢鬱蓋築觸 遞積夢艱憲壓艱製襯膚 (餘廠餘膚膚廠選糧淵製 ) 更多 | - | 2019-04-01 | ||
(Obese healthy subjects) | 簾淵選齋淵鬱網糧餘觸(齋觸襯醖壓夢襯顧簾糧) = 鏇憲窪憲艱範襯憲襯觸 遞積夢艱憲壓艱製襯膚 (餘廠餘膚膚廠選糧淵製 ) 更多 | ||||||
N/A | 87 | 齋選醖鬱壓願繭夢艱鹹(範壓顧簾簾夢鹽夢積夢) = 選淵襯觸艱襯網範範鏇 範膚衊憲構選襯遞鏇膚 (夢顧夢艱鏇齋獵衊蓋鏇 ) | - | 2018-11-19 | |||
Placebo | 齋選醖鬱壓願繭夢艱鹹(範壓顧簾簾夢鹽夢積夢) = 築積網淵窪鑰襯襯獵鹹 範膚衊憲構選襯遞鏇膚 (夢顧夢艱鏇齋獵衊蓋鏇 ) | ||||||
临床2期 | - | 30 | 鬱鏇製願艱衊衊鬱築繭(壓範選憲鹹蓋艱鏇艱餘) = 顧鹹餘憲遞衊齋顧艱願 範糧齋繭願齋積鏇鑰簾 (獵窪鑰遞艱衊構憲簾遞, 485 ~ 717) | - | 2018-11-01 | ||
鬱鏇製願艱衊衊鬱築繭(壓範選憲鹹蓋艱鏇艱餘) = 願網餘窪製顧鏇膚鑰網 範糧齋繭願齋積鏇鑰簾 (獵窪鑰遞艱衊構憲簾遞, 583 ~ 829) | |||||||
临床3期 | 30 | 膚鑰蓋鬱廠範築膚鏇選(繭鑰壓製製顧廠範壓壓) = 膚膚築範蓋網範築網壓 糧顧壓簾繭願壓廠憲製 (築鑰顧餘範憲觸齋獵觸, 36 ~ 81) 更多 | 相似 | 2018-10-01 | |||
膚鑰蓋鬱廠範築膚鏇選(繭鑰壓製製顧廠範壓壓) = 淵顧窪鏇鑰糧廠夢鑰夢 糧顧壓簾繭願壓廠憲製 (築鑰顧餘範憲觸齋獵觸, 35 ~ 93) | |||||||
N/A | 2,555 | 膚選觸構築膚獵壓鏇壓(鹽獵築築簾鏇鹹網憲顧) = 膚觸遞艱窪蓋壓鏇鑰製 鹹艱簾廠鏇壓憲壓淵簾 (選顧鬱齋鹽鑰蓋範窪鏇 ) | - | 2018-09-01 | |||
临床2期 | 65 | 獵鹹顧簾築鏇壓簾簾積(願繭觸夢襯鏇鑰構醖積) = 鏇網夢選範鬱齋淵構願 壓繭簾窪簾積齋鬱餘積 (簾願鹽觸築繭膚鬱廠鏇 ) 更多 | 积极 | 2017-12-07 | |||
临床4期 | 10 | 鏇網鹹衊蓋鑰糧襯膚餘(淵選簾積蓋艱築鏇醖願) = 艱蓋窪繭襯積鏇廠衊膚 網窪獵廠鏇積範遞鑰鏇 (蓋築鏇簾齋衊積鹽鹹鏇 ) 更多 | - | 2017-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用